

Patent  
HDAC-5005-C2

1RW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Jerome C. Bressi et al.

Serial No.: 10/803,580

Filed: March 17, 2004

For: HISTONE DEACETYLASE  
INHIBITORS

)  
) Group Art Unit: 1625

)  
) Examiner: Celia C. Chang

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449, and copies of the non-US patent references are included for the Examiner's convenience.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicants as such.

CERTIFICATE OF HAND DELIVERY

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being delivered via hand delivery to the Commissioner for Patents, Randolph Building, 401 Dulany Street, Alexandria, Virginia 22314.

8/1/06  
Date of Deposit

John Sam Klose  
Name of Person Delivering Paper  
John Sam Klose  
Signature of Person Delivering Paper

**INFORMATION DISCLOSURE STATEMENT FILING PROVISION:**

☒ This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application filed under § 1.53(d); or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.

☒ However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR § 1.17(p) to the deposit account referenced below.

☐ However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required.

☐ This IDS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action on the merits, but before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311.

☐ The fee due under 37 CFR § 1.17(p) is submitted herewith.

☐ A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.

☐ This IDS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311, but before payment of the issue fee. A statement under 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted herewith.

**STATEMENT UNDER 37 CFR § 1.97(e):**

☐ Each item contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.

☐ No item contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing

this statement after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this IDS.

**PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:**

- ☐ A check in the amount of \_\_\_\_\_ is enclosed for the above fee(s).  
☐ Please charge to Deposit Account No. **50-2256** for the above fee(s).


Although Applicants do not believe any fees are required, the Commissioner is authorized to charge any fees required by the filing of these papers to Takeda's Deposit Account No. **50-2256**.

Respectfully submitted,


TAKEDA SAN DIEGO, INC.

Dated: July 31, 2006

By: \_\_\_\_\_

  
C. Amy Smith  
Reg. No. 42,931

Customer No. **32793**  
Takeda San Diego, Inc.  
10410 Science Center Drive  
San Diego, CA 92121  
Tel: (858) 622-8528  
Fax: (858) 550-0992



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/803,580		
		Filing Date	March 17, 2004		
		First Named Inventor	Jerome C. Bressi		
		Group Art Unit	1625		
		Examiner Name	Celia C. Chang		
Sheet	1	of	15	Attorney Docket Number	HDAC-5005-C2

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	AA	US 4,482,571	11/13/1984	Abraham Donald J.	
	AB	US 4,997,815	3/5/1991	Perrine Susan P. et al	
	AC	US 5,124,342	6/23/1992	Kerdesky Francis A. J. et al.	
	AD	US 5,216,004	6/1/1993	Perrine Susan P.	
	AE	US 5,439,939	8/8/1995	Perrine Susan P.	
	AF	US 5,569,675	10/29/1996	Rephaeli Ada et al.	
	AG	US 5,645,852	7/8/1997	Newmark Harold L.	
	AH	US 5,656,644	8/12/1997	Adams Jerry Leroy et al.	
	AI	US 5,700,826	12/23/1997	Mijali Adnan et al.	
	AJ	US 5,858,365	1/12/1999	Faller Douglas V	
	AK	US 5,922,837	7/13/1999	Meinke Peter T. et al.	
	AL	US 5,939,455	8/17/1999	Rephaeli Ada	
	AM	US 5,939,456	8/17/1999	Perrine Susan P.	
	AN	US 5,993,845	11/30/1999	Geerts Albert Emmanuel Comeille et al.	
	AO	US 6,011,000	1/4/2000	Perrine Susan P. et al.	
	AP	US 6,030,961	2/29/2000	Nudelman Abraham et al.	
	AQ	US 6,040,342	3/21/2000	Rephaeli Ada et al.	
	AR	US 6,043,277	3/28/2000	Rephaeli Ada et al.	
	AS	US 6,043,389	3/28/2000	Nudelman Abraham et al.	
	AT	US 6,068,987	5/30/2000	Dulski Paula M. et al.	
	AU	US 6,071,923	6/6/2000	Nudelman Abraham et al	
	AV	US 6,110,697	8/29/2000	Dulski Paula M. et al.	
	AW	US 6,110,955	8/29/2000	Nudelman Abraham et al.	
	AX	US 6,110,970	8/29/2000	Nudelman Abraham et al.	
	AY	US 6,110,697	8/29/2000	Dulski Paula M. et al.	
	AZ	US 6,124,495	9/26/2000	Neiss Edward et al.	
	BA	US 6,130,248	10/10/2000	Nudelman Abraham et al.	
	BB	US 6,174,905	1/16/2001	Suzuki Tsuneji et al.	
	BC	US 6,197,743	3/6/2001	Faller Douglas V.	
	BD	US 6,231,880	5/15/2001	Perrine Susan P.	
	BE	US 6,235,474	5/22/2001	Feinberg Andrew P.	
	BF	US 6,239,176	5/29/2001	Nudelman Abraham et al.	
	BG	US 6,262,116	7/17/2001	Pandolfi Pier Paolo et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/803,580
		Filing Date	March 17, 2004
		First Named Inventor	Jerome C. Bressi
		Group Art Unit	1625
		Examiner Name	Celia C. Chang
Sheet 2 of 15	Attorney Docket Number	HDAC-5005-C2	

	BH	US 2001/0009922A1	7/26/2001	Faller Douglas V.	
	BI	US 2001/0012836A1	8/9/2001	Hu Erding et al.	
	BJ	US 6,287,790	9/11/2001	Lelievre Sophie et al.	
	BK	US 2001/0027215A1	10/4/2001	Perrine Susan P. et al	
	BL	US 2001/0034367A1	10/25/2001	Faller Douglas V. et al.	
	BM	US 6,329,402	12/11/2001	Kikuchi Kouichi et al.	
	BN	US 6,335,170	1/1/2002	Orntoft Torben F.	
	BO	US 6,372,957	4/16/2002	Olson Eric N.	
	BP	US 6,376,508	4/23/2002	Li Hung et al.	
	BQ	US 6,387,673	5/14/2002	Evans Ronald M. et al.	
	BR	US 2002/0061860A1	5/23/2002	Li Zuomei et al.	
	BS	US 2002/0065282A1	5/30/2002	Georges Guy et al.	
	BT	US 6,399,568	6/4/2002	Nishino Norikazu et al.	
	BU	US 6,403,555	6/11/2002	Skov S.	
	BV	US 2002/0076457A1	6/20/2002	Aylward James Harrison	
	BW	US 2002/0103192A1	8/1/2002	Curtin Michael L. et al.	
	BX	US 6,428,983	8/6/2002	Dulski Paula M. et al.	
	BY	US 2002/0107404A1	8/8/2002	Prien Olaf et al.	
	BZ	US 2002/0115177A1	8/22/2002	Zhu Zimin	
	CA	US 2002/0115826A1	8/22/2002	Delorme Daniel et al.	
	CB	US 2002/0120099A1	8/29/2002	Nishino Norikazu et al.	
	CC	US 2002/0119996A1	8/29/2002	Lan-Hargest Hsuan-Yin et al.	
	CD	US 6,451,334	9/17/2002	Perrine Susan P. et al	
	CE	US 2002/0132792A1	9/19/2002	Prien Olaf et al.	
	CF	US 2002/0137162A1	9/26/2002	Li Zuomei et al.	
	CG	US 2002/0137775A1	9/26/2002	Lan-Hargest Hsuan-Yin et al.	
	CH	US 2002/0143037A1	10/3/2002	Lan-Hargest Hsuan-Yin et al.	
	CI	US 2002/0143052A1	10/3/2002	Lan-Hargest Hsuan-Yin et al.	
	CJ	US 2002/0143055A1	10/3/2002	Lan-Hargest Hsuan-Yin et al.	
	CK	US 2002/0143196A1	10/3/2002	Lan-Hargest Hsuan-Yin et al.	
	CL	US 2002/0161045A1	10/31/2002	Lan-Hargest Hsuan-Yin et al.	
	CM	US 2002/0164752A1	11/7/2002	Meyers Rachel A.	
	CN	US 6,479,629	11/12/2002	Baldwin Donald Adelphi et al.	
	CO	US 2002/0177594A1	11/28/2002	Curtin Michael L. et al.	
	CP	US 2002/0183388A1	12/5/2002	Gudas Lorraine J.	
	CQ	US 2002/0183513A1	12/5/2002	Grossmann Adelbert et al.	
	CR	US 6,495,719	12/17/2002	Lan-Hargest Hsuan-Yin et al.	
	CS	US 6,506,574	1/14/2003	Rambhatla Lakshmi et al.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/803,580		
		Filing Date	March 17, 2004		
		First Named Inventor	Jerome C. Bressi		
		Group Art Unit	1625		
		Examiner Name	Celia C. Chang		
Sheet	3	of	15	Attorney Docket Number	HDAC-5005-C2

	CT	US 2003/0013176A1	1/16/2003	Pavletich Nikola et al.	
	CU	US 2003/0013757A1	1/16/2003	Leser-Reiff Ulrike et al.	
	CV	US 2003/0017454A1	1/23/2003	Sukumar Saraswati et al.	
	CW	US 2003/0018062A1	1/23/2003	Remiszewski Stacy W. et al.	
	CX	US 6,512,123	1/28/2003	Grossmann Adelbert et al.	
	CY	US 6,511,990	1/28/2003	Breslow Ronald et al.	
	CZ	US 6,518,012	2/11/2003	Tomasi Thomas B.	
	DA	US 6,531,472	3/11/2003	Georges Guy et al.	
	DB	US 6,538,030	3/25/2003	Chung Yih-Lin et al.	
	DC	US 2003/0059812A1	3/27/2003	Richon Victoria M. et al.	
	DD	US 6,541,661	4/1/2003	Delorme Daniel et al.	
	DE	US 6,544,957	4/8/2003	Kem Scott E. et al.	
	DF	US 6,548,479	4/15/2003	Skov S.	
	DG	US 6,552,065	4/22/2003	Remiszewski Stacy William et al.	
	DH	US 2003/0078216A1	4/24/2003	MacLeod A. Robert et al.	
	DI	US 2003/0078369A1	4/24/2003	Meinke Peter T. et al.	
	DJ	US 2003/0082668A1	5/1/2003	Tamai Katsuyuki et al.	
	DK	US 2003/0082666A1	5/1/2003	Kammer Gary M. et al.	
	DL	US 2003/0083521A1	5/1/2003	Lan-Hargest Hsuan-Yin et al.	
	DM	US 6,562,995	5/13/2003	Lan-Hargest Hsuan-Yin et al.	
	DN	US 2003/0124101A1	7/3/2003	Gu Wei et al.	
	DO	US 2003/0125306A1	7/3/2003	Lan-Hargest Hsuan-Yin et al.	
	DP	US 2003/0129724A1	7/10/2003	Grozinger Christina M. et al.	
	DQ	US 2003/0134865A1	7/17/2003	Adcock Ian et al.	
	DR	US 2003/0139404A1	7/24/2003	Haag Rainer et al.	
	DS	US 6,599,937	7/29/2003	Neiss Edward et al.	
	DT	US 2003/0143712A1	7/31/2003	Verdin Eric et al.	
	DU	US 2003/0144340A1	7/31/2003	Long Carlin et al.	
	DV	US 2003/0144276A1	7/31/2003	Kikuchi Kouichi et al.	
	DW	US 2003/0144340A1	7/31/2003	Long Carlin et al.	
	DX	US 2003/0149261A1	8/7/2003	Schramm Vern L. et al.	
	DY	US 2003/0148970A1	8/7/2003	Besterman Jeffrey M. et al.	
	DZ	US 2003/0154032A1	8/14/2003	Pittman Debra D. et al.	
	EA	US 2003/0152557A1	8/14/2003	Besterman Jeffrey M. et al.	
	EB	US 2003/0165956A1	9/4/2003	Stevens Craig W. et al.	
	EC	US 2003/0165903A1	9/4/2003	Dang Van-Dinh et al.	
	ED	US 2003/0171409A1	9/11/2003	Lan-Hargest Hsuan-Yin et al.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/803,580		
		Filing Date	March 17, 2004		
		First Named Inventor	Jerome C. Bressi		
		Group Art Unit	1625		
		Examiner Name	Celia C. Chang		
Sheet	4	of	15	Attorney Docket Number	HDAC-5005-C2

	EE	US 2003/0187027A1	10/2/2003	Schreiber Stuart L. et al.	
	EF	US 6,632,628	10/14/2003	Olson Eric N. et al.	
	EG	US 6,638,530	10/28/2003	Ishibashi Masahiko et al.	
	EH	US 2003/0207791A1	11/6/2003	Minucci Saverio et al.	
	EI	US 2003/0207325A1	11/6/2003	Guarente Leonard P. et al.	
	EJ	US 2003/0206946A1	11/6/2003	Chung Yih-Lin	
	EK	US 2003/0212121A1	11/13/2003	Kruger Martin et al.	
	EL	US 2003/0216345A1	11/20/2003	Nakanishi Osamu et al.	
	EM	US 2003/0219832A1	11/27/2003	Klein Elliott S. et al.	
	EN	US 6,656,905	12/2/2003	Mori Hiroaki et al.	
	EO	US 2003/0224473A1	12/4/2003	McCafferty Dewey G.	
	EP	US 2003/0224040A1	12/4/2003	Baylin Stephen B. et al.	
	EQ	US 2003/0235873A1	12/25/2003	Krmer Joachim et al.	
	ER	US 2004/0002506A1	1/1/2004	Breslow Ronald et al.	
	ES	US 2004/0002447A1	1/1/2004	Levine Fred et al.	
	ET	US 2004/0002506A1	1/1/2004	Breslow Ronald et al.	
	EU	US 6,673,587	1/6/2004	Evans Ronald M.	
	EV	US 2004/0005574A1	1/8/2004	Guarente Leonard et al.	
	EW	US 2004/0014647A1	1/22/2004	Lee Hyang Woo et al.	
	EX	US 2004/0018968A1	1/29/2004	Sgouros George et al.	
	EY	US 2004/0018522A1	1/29/2004	Dangond Fernando et al.	
	EZ	US 2004/0024067A1	2/5/2004	Remiszewski Stacy William et al.	
	FA	US 2004/0023944A1	2/5/2004	Lan-Hargest Hsuan-Yin et al.	
	FB	US 6,689,558	2/10/2004	Case Casey	
	FC	US 2004/0028607A1	2/12/2004	Verdin Eric M. et al.	
	FD	US 2004/0029922A1	2/12/2004	Lan-Hargest Hsuan-Yin et al.	
	FE	US 2004/0029903A1	2/12/2004	Lan-Hargest Hsuan-Yin et al.	
	FF	US 6,699,902	3/2/2004	Lan-Hargest Hsuan-Yin et al.	
	FG	US 2004/0043470A1	3/4/2004	Xiao Yonghong	
	FH	US 6,706,762	3/16/2004	Evans Ronald M. et al.	
	FI	US 6,706,686	3/16/2004	Long Carlin et al.	
	FJ	US 2004/0053820A1	3/18/2004	Nakajima Hidenori et al.	
	FK	US 2004/0053960A1	3/18/2004	Georges Guy et al.	
	FL	US 2004/0058868A1	3/25/2004	James Stephen et al.	
	FM	US 6,720,445	4/13/2004	Lan-Hargest Hsuan-Yin et al.	
	FN	US 2004/0072735A1	4/15/2004	Richon Victoria M. et al.	
	FO	US 2004/0072770A1	4/15/2004	Besterman Jeffrey M. et al.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/803,580		
		Filing Date	March 17, 2004		
		First Named Inventor	Jerome C. Bressi		
		Group Art Unit	1625		
		Examiner Name	Celia C. Chang		
Sheet	5	of	15	Attorney Docket Number	HDAC-5005-C2

	FP	US 2004/0072849A1	4/15/2004	Schreiber Stuart L. et al.	
	FQ	US 2004/0077578A1	4/22/2004	Monia Brett P. et al.	
	FR	US 2004/0077084A1	4/22/2004	Watt Andrew T. et al.	
	FS	US 2004/0077083A1	4/22/2004	Watt Andrew T.	
	FT	US 2004/0077046A1	4/22/2004	Cohen Dalia et al.	
	FU	US 2004/0077591A1	4/22/2004	Dangond Fernando	
	FV	US 2004/0077726A1	4/22/2004	Watkins Clare J. et al.	
	FW	US 2004/0077698A1	4/22/2004	Georges Guy et al.	
	FX	US 2004/0081976A1	4/29/2004	Sidransky David	
	FY	US 2004/0087657A1	5/6/2004	Richon Victoria M. et al.	
	FZ	US 2004/0087652A1	5/6/2004	Gottlicher Martin et al.	
	GA	US 2004/0087631A1	5/6/2004	Bacopoulos Nicholas G. et al.	
	GB	US 2004/0091967A1	5/13/2004	Kohler Ranier H	
	GC	US 2004/0091953A1	5/13/2004	Verdin Eric M. et al.	
	GD	US 2004/0091951A1	5/13/2004	Schultz Brian E.	
	GE	US 2004/0092558A1	5/13/2004	Klimko Peter G. et al.	
	GF	US 2004/0092431A1	5/13/2004	Hellberg Peggy E.	
	GG	US 2004/0092598A1	5/13/2004	Watkins Clare J. et al.	
	GH	US 2004/0092572A1	5/13/2004	Renaud Johanne et al.	
	GI	US 2004/0097439A9	5/20/2004	Nicolas Jean-Francois et al.	
	GJ	US 2004/0102458A1	5/27/2004	Chiosis Gabriela et al.	
	GK	US 2004/0106599A1	6/3/2004	Delorme Daniel et al.	
	GL	US 2004/0122101A1	6/24/2004	Miller Thomas A. et al.	
	GM	US 2004/0122079A1	6/24/2004	Grossmann Adelbert et al.	
	GN	US 2004/0127571A1	7/1/2004	Bhalla Kapil N. et al.	
	GO	US 2004/0127523A1	7/1/2004	Bacopoulos Nicholas G. et al.	
	GP	US 2004/0127522A1	7/1/2004	Chiao Judy H. et al.	
	GQ	US 2004/0138270A1	7/15/2004	George Fertig et al.	
	GR	US 2004/0157930A1	8/12/2004	Mascagni Paolo et al.	
	GS	US 2004/0157924A1	8/12/2004	Lan-Hargest Hsuan-Yin et al.	
	GT	US 2004/0157841A1	8/12/2004	Fertig Georg et al.	
	GU	US 6,777,217	8/17/2004	Schreiber Stuart L. et al.	
	GV	US 2004/0161787A1	8/19/2004	Michnick Stephen William Watson et al.	
	GW	US 2004/0162317A1	8/19/2004	Fertig Georg et al.	
	GX	US 2004/0167184A1	8/26/2004	Wiech Norbert L. et al.	
	GY	US 6,784,173	8/31/2004	Leser-Reiff Ulrike et al.	
	GZ	US 2004/0180962A1	9/16/2004	Truog Peter	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/803,580		
		Filing Date	March 17, 2004		
		First Named Inventor	Jerome C. Bressi		
		Group Art Unit	1625		
		Examiner Name	Celia C. Chang		
Sheet	6	of	15	Attorney Docket Number	HDAC-5005-C2

	HA	US 2004/0186274A1	9/23/2004	Allis C. David et al.	
	HB	US 2004/0186049A1	9/23/2004	Long Carlin et al.	
	HC	US 2004/0192744A1	9/30/2004	Haag Rainer et al.	
	HD	US 6,800,638	10/5/2004	Georges Guy et al.	
	HE	US 2004/0197888A1	10/7/2004	Christopher D. Amour et al.	
	HF	US 2004/0198830A1	10/7/2004	Watkins, Claire J. et al.	
	HG	US 2004/0204373A1	10/14/2004	Monia Brett P. et al.	
	HH	US 2004/0204339A1	10/14/2004	DiMartino Jorge F.	
	HI	US 6,809,118	10/26/2004	Chung Yih-Lin	
	HJ	US 2004/0213826A1	10/28/2004	Marx Steven O. et al.	
	HK	US 2004/0214880A1	10/28/2004	Fertig Georg et al.	
	HL	US 2004/0214862A1	10/28/2004	Leser-Reiff Ulrike et al.	
	HM	US 2004/0224991A1	11/11/2004	Lu Xian-Ping et al.	
	HN	US 2004/0229889A1	11/18/2004	Urano Yasuharu et al.	
	HO	US 6,825,317	11/30/2004	Nishino Norikazu et al.	
	HP	US 6,828,302	12/7/2004	Skov S.	
	HQ	US 6,831,061	12/14/2004	Lee Hyang Woo et al.	
	HR	US 2004/0254220A1	12/16/2004	Bressi Jerome C. et al.	
	HS	US 6,833,384	12/21/2004	Remiszewski Stacy William et al.	
	HT	US 2004/0259772A1	12/23/2004	Fojo Antonio et al.	
	HU	US 2004/0266718A1	12/30/2004	Li Zuomei et al.	
	HV	US 2004/0266818A1	12/30/2004	Breslow Ronald et al.	
	HW	US 2004/0266769A1	12/30/2004	Bressi Jerome C. et al.	
	HX	US 2005/0003031A1	1/6/2005	Aylward James Harrison	
	HY	US 6,841,565	1/11/2005	Lucas David M. et al.	
	HZ	US 2005/0009030A1	1/13/2005	Schweighoffer Fabien et al.	
	IA	US 2005/0020557A1	1/27/2005	Johnson Robert JR. et al.	
	IB	US 2005/0026907A1	2/3/2005	Wash Paul L. et al.	
	IC	US 2005/0032899A1	2/10/2005	Chen Ying-Nan Pan et al.	
	ID	US 2005/0032831A1	2/10/2005	Kozikowski Alan P. et al.	
	IE	US 2005/0032794A1	2/10/2005	Padia Janak K. et al.	
	IF	US 2005/0038113A1	2/17/2005	Groner Bernd et al.	
	IG	US 2005/0037992A1	2/17/2005	Lyons John et al.	
	IH	US 2005/0059682A1	3/17/2005	Rubinfeld Joseph	
	II	US 6,869,953	3/22/2005	Haag Rainer et al.	
	IJ	US 2005/0065596A1	3/24/2005	Tseng Xufan et al.	
	IK	US 2005/0070467A1	3/31/2005	Naoe Yoshinori	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/803,580		
		Filing Date	March 17, 2004		
		First Named Inventor	Jerome C. Bressi		
		Group Art Unit	1625		
		Examiner Name	Celia C. Chang		
Sheet	7	of	15	Attorney Docket Number	HDAC-5005-C2

	IL	US 6,875,598	4/5/2005	Buggy Joseph	
	IM	US 2005/0080249A1	4/14/2005	Buggy Joseph	
	IN	US 2005/0079995A1	4/14/2005	Bedaloy Antonio et al.	
	IO	US 2005/0085515A1	4/21/2005	Watkins Clare J. et al.	
	IP	US 2005/0084967A1	4/21/2005	Berenson Ronald J. et al.	
	IQ	US 2005/0085507A1	4/21/2005	Remiszewski Stacy William et al.	
	IR	US 2005/0085515A1	4/21/2005	Watkins Clare J. et al.	
	IS	US 6,884,597	4/26/2005	Taya Yoichi et al.	
	IT	US 6,888,027	5/3/2005	Watkins Clare J. et al.	
	IU	US 2005/0096468A1	5/5/2005	Van Emelen Kristof et al.	
	IV	US 2005/0107445A1	5/19/2005	Watkins Clare J. et al.	
	IW	US 2005/0106654A1	5/19/2005	Olson Eric N. et al.	
	IX	US 2005/0107445A1	5/19/2005	Watkins Clare J. et al.	
	IY	US 2005/0107384A1	5/19/2005	Angibaud Patrick Rene et al.	
	IZ	US 2005/0107348A1	5/19/2005	Lan-Hargest Hsuan-Yin et al.	
	JA	US 6,897,220	5/24/2005	Delorme Daniel et al.	
	JB	US 2005/0113373A1	5/26/2005	Van Emelen Kristof et al.	
	JC	US 2005/0118596A1	6/2/2005	Asselbergs Fredericus Alphonsus Maria et al.	
	JD	US 2005/0119250A1	6/2/2005	Angibaud Patrick Rene et al.	
	JE	US 2005/0124679A1	6/9/2005	Kim Dae-Kee et al.	
	JF	US 6,905,669	6/14/2005	DiMartino Jorge F.	
	JG	US 2005/0130146A1	6/16/2005	Zelent Arthur et al.	
	JH	US 2005/0131018A1	6/16/2005	Sendzik Martin et al.	
	JI	US 2005/0137234A1	6/23/2005	Bressi Jerome C. et al.	
	JJ	US 2005/0137232A1	6/23/2005	Bressi Jerome C. et al.	
	JK	US 2005/0136090A1	6/23/2005	Falotico Robert et al.	
	JL	US 2005/0143385A1	6/30/2005	Watkins Clare J. et al.	
	JM	US 2005/0148613A1	7/7/2005	Van Emelen Kristof et al.	
	JN	US 2005/0159347A1	7/21/2005	DiMartino Jorge F.	
	JO	US 2005/0159470A1	7/21/2005	Bressi Jerome C. et al.	
	JP	US 2005/0165016A1	7/28/2005	Van Emelen Kristof	
	JQ	US 2005/0171042A1	8/4/2005	Monia Brett P. et al.	
	JR	US 2005/0171027A1	8/4/2005	Sinclair David A. et al.	
	JS	US 2005/0171347A1	8/4/2005	Emelen Kristof Van et al.	
	JT	US 2005/0171208A1	8/4/2005	Lan-Hargest Hsuan-Yin et al.	
	JU	US 2005/0171103A1	8/4/2005	Stokes Elaine Sophie Elizabeth et al.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/803,580		
		Filing Date	March 17, 2004		
		First Named Inventor	Jerome C. Bressi		
		Group Art Unit	1625		
		Examiner Name	Celia C. Chang		
Sheet	8	of	15	Attorney Docket Number	HDAC-5005-C2

	JV	US 2005/0176764A1	8/11/2005	Mataki Chikage et al.	
	JW	US 2005/0176686A1	8/11/2005	Maurer Alexander B. et al.	
	JX	US 2005/0187261A1	8/25/2005	Verner Erik J. et al.	
	JY	US 2005/0191713A1	9/1/2005	Sasakawa Yuka et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> – Number <sup>4</sup> – Kind Code <sup>5</sup> ( <i>if known</i> )				
	JZ	WO 96/15096 A1	5/23/1996	BAYER CORPORATION		
	KA	WO 97/02244 A1	1/23/1997	EISAI CO., LTD.,		
	KB	WO 97/11366 A1	3/27/1997	MERCK & CO., INC.		
	KC	WO 97/35990 A2 & A3	10/2/1997	PRESIDENT AND FELLOWS OF HARVARD COLLEGE		
	KD	WO 97/47307 A1	12/18/1997	UAB RESEARCH FOUNDATION		
	KE	WO 98/00127 A1	1/8/1998	REPHELI, Ada		
	KF	WO 98/28269 A1	7/2/1998	THE DUPONT MERCK PHARMACEUTICAL COMPANY		
	KG	WO 98/29114 A1	7/9/1998	BEACON LABORATORIES L.L.C.		
	KH	WO 98/39966 A1	9/17/1998	BEACON LABORATORIES, L.L.C.		
	KI	WO 98/40065 A1	9/17/1998	BEACON LABORATORIES, L.L.C.		
	KJ	WO 98/40080 A1	9/17/1998	MOR RESEARCH APPLICATIONS, LTD.		
	KK	WO 98/48825 A1	11/05/1998	SALK INSTITUTE FOR BIOLOGICAL STUDIES		
	KL	WO 98/55449 A1	12/10/1998	QUEENSLAND INSTITUTE OF MEDICAL RESEARCH		
	KM	WO 99/11659 A1	3/11/1999	JAPAN ENERGY CORPORATION		
	KN	WO 99/23885 A1	5/20/1999	SALK INSTITUTE FOR BIOLOGICAL STUDIES		
	KO	WO 99/37150 A1	7/29/1999	SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH		
	KP	WO 99/61413 A1	12/2/1999	BAYER CORPORATION		
	KQ	WO 00/08048 A2 & A3	2/17/2000	FUJISAWA PHARMACEUTICAL CO., LTD.		
	KR	WO 00/010583 A1	3/2/2000	SMITHKLINE BEECHAM CORPORATION		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/803,580
		Filing Date	March 17, 2004
		First Named Inventor	Jerome C. Bressi
		Group Art Unit	1625
		Examiner Name	Celia C. Chang
Sheet 9 of 15	Attorney Docket Number	HDAC-5005-C2	

	KS	WO 00/021979 A2 & A3	4/20/2000	FUJISAWA PHARMACEUTICAL CO., LTD.		
	KT	WO 00/023567 A2 & A3	4/27/2000	NOVARTIS AG		
	KU	WO 00/52033 A1	9/8/2000	JAPAN ENERGY CORPORATION		
	KV	WO 00/56917 A1	9/28/2000	CHUGAI RESEARCH INSTITUTE FOR MOLECULAR MEDICINE, INC.		
	KW	WO 00/118045 A1	10/8/2000	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH		
	KX	WO 00/61576 A1	10/19/2000	SMITHKLINE BEECHAM CORPORATION		
	KY	WO 00/71703 A2 & A3	11/30/2000	METHYLGENE INC.		
	KZ	WO 01/07042 A1	2/1/2001	MERCK & CO., INC.		
	LA	WO 01/14581 A3	3/1/2001	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM		
	LB	WO 01/16106 A1	3/8/2001	SCHERING AKTIENGESELLSCHAFT		
	LC	WO 01/17514 A1	3/15/2001	SALK INSTITUTE OF BIOLOGICAL STUDIES		
	LD	WO 01/018045 A1	3/15/2001	TRUSTEES OF COLUMBIA UNIVERSITY IN CITY OF NEW YORK		
	LE	WO 01/18171 A2 & A3	3/15/2001	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH		
	LF	WO 01/27314 A1	4/19/2001	MERCK & CO., INC.		
	LG	WO 01/38322 A1	5/31/2001	METHYLGENE, INC.		
	LH	WO 01/42437 A2 & A3	6/14/2001	AXYS PHARMACEUTICALS, INC.		
	LI	WO 01/67107 A1	9/13/2001	IMPERIAL COLLEGE INNOVATIONS LIMITED		
	LJ	WO 01/70675 A3	9/27/2001	METHYLGENE, INC.		
	LK	WO 01/72784 A2 & A3	10/4/2001	FILGEN BIOSCIENCES, INC.		
	LL	WO 01/72737 A1	10/4/2001	SMITHKLINE BEECHAM CORPORATION		
	LM	WO 02/06307 A1	1/24/2002	FUJISAWA PHARMACEUTICAL CO., LTD.		
	LN	WO 02/08273 A2 & A3	1/31/2002	MILLENNIUM PHARMACEUTICALS, INC.		
	LO	WO 02/07722 A2 & A3	1/31/2002	GEORG-SPEYER-HAUS		
	LP	WO 02/15921 A2 & A3	2/28/2002	GOVERNMENT OF UNITED STATES OF AMERICA, represented by SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES		
	LQ	WO 02/22133 A1	3/21/2002	VIRGINIA COMMONWEALTH UNIVERSITY		
	LR	WO 02/22577 A3	3/21/2002	NOVARTIS AG		
	LS	WO 02/26696 A1	4/4/2002	PROLIFIX LIMITED		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/803,580
		Filing Date	March 17, 2004
		First Named Inventor	Jerome C. Bressi
		Group Art Unit	1625
		Examiner Name	Celia C. Chang
Sheet 10 of 15	Attorney Docket Number	HDAC-5005-C2	

	LT	WO 02/26703 A1	4/4/2002	PROLIFIX LIMITED		
	LU	WO 02/30879 A2 & A3	4/18/2002	PROLIFIX LIMITED		
	LV	WO 02/30970 A2 & A3	4/18/2002	BAYER AKTIENGESELLSCHAFT		
	LW	WO 02/36783 A2 & A3	5/10/2002	BAYER AKTIENGESELLSCHAFT		
	LX	WO 02/36075 A2 & A3	5/10/2002	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH		
	LY	WO 02/46144 A1	6/13/2002	F. HOFFMANN-LA ROCHE AG		
	LZ	WO 02/46129 A2 & A3	6/13/2002	ABBOTT LABORATORIES		
	MA	WO 02/50244 A3	6/27/2002	ISIS PHARMACEUTICALS, INC.		
	MB	WO 02/50285 A2 & A3	6/27/2002	NOVARTIS AG		
	MC	WO 02/051842 A1	7/4/2002	F. HOFFMANN-LA ROCHE AG		
	MD	WO 02/055017 A3	7/18/2002	WAKE FOREST UNIVERSITY		
	ME	WO 02/055688 A2 & A3	7/18/2002	GOVERNMENT OF UNITED STATES OF AMERICA, as represented by SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES		
	MF	WO 02/060430 A1	8/8/2002	CORNELL RESEARCH FOUNDATION, INC.		
	MG	WO 02/062773 A1	8/15/2002	F. HOFFMANN-LA ROCHE AG		
	MH	WO 02/069947 A2 & A3	9/12/2002	METHYLGENE, INC.		
	MI	WO 2002/076941 A2 & A3	10/3/2002	CIRCADEN PHARMACEUTICAL		
	MJ	WO 02/083173 A1	10/24/2002	DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS		
	MK	WO 02/085400 A1	10/31/2002	SUPERGEN, INC.		
	ML	WO 02/085883 A1	10/31/2002	F. HOFFMANN-LA ROCHE AG		
	MM	WO 02/089782 A2 & A3	11/14/2002	PRESIDENT AND FELLOWS OF HARVARD COLLEGE		
	MN	WO 02090534 A1	11/14/2002	REGENTS OF UNIVERSITY OF CALIFORNIA		
	MO	WO 02/102316 A2 & A3	12/27/2002	REGENTS OF THE UNIVERSITY OF CALIFORNIA		
	MP	WO 02/102323 A2	12/27/2002	BRISTOL-MYERS SQUIBB COMPANY		
	MQ	WO 02/102984 A2 & A3	12/27/2002	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH		
	MR	WO 03/000715 A1	1/3/2003	CERES, INC.		
	MS	WO 2003/006652 A2 & A3	1/23/2003	METHYLGENE, INC.		
	MT	WO 03/011851 A3	2/13/2003	F. HOFFMAN-LA ROCHE AG		
	MU	WO 03/013493 A1	2/20/2003	ITALFARMACO S.P.A.		
	MV	WO 03/014340 A2 & A3	2/20/2003	NOVARTIS AG		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/803,580
		Filing Date	March 17, 2004
		First Named Inventor	Jerome C. Bressi
		Group Art Unit	1625
		Examiner Name	Celia C. Chang
Sheet 11 of 15	Attorney Docket Number	HDAC-5005-C2	

	MW	WO 03/015810 A1	2/27/2003	FUJISAWA PHARMACEUTICAL CO., LTD.		
	MX	WO 03/024442 A2 & A3	3/27/2003	G2M CANCER DRUGS AG		
	MY	WO 03/024448 A2 & A3	3/27/2003	METHYLGENE, INC.		
	MZ	WO 03/029451 A2 & A3	4/10/2003	INSTITUTE OF CANCER RESEARCH		
	NA	WO 03/032921 A2 & A3	4/24/2003	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH		
	NB	WO 03/033678 A3	4/24/2003	SALK INSTITUTE FOR BIOLOGICAL STUDIES		
	NC	WO 03/039599 A1	5/15/2003	NOVARTIS AG		
	ND	WO 03/046207 A2	6/5/2003	FRED HUTCHINSON CANCER RESEARCH CENTER		
	NE	WO 03/048774 A1	6/12/2003	NOVARTIS AG		
	NF	WO 03/053468 A1	7/3/2003	UNIVERSITE LIBRE DE BRUXELLES		
	NG	WO 03/057722 A2 & A3	7/17/2003	FUJISAWA PHARMACEUTICAL CO., LTD.		
	NH	WO 03/059864 A2 & A3	7/24/2003	SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.		
	NI	WO 03/066579 A2 & A3	8/14/2003	AXYS PHARMACEUTICALS		
	NJ	WO 03/066885 A2 & A3	8/14/2003	NOVARTIS AG		
	NK	WO 03/066889 A2 & A3	8/14/2003	AXYS PHARMACEUTICALS, INC.		
	NL	WO 2003/070188 A2 & A3	8/28/2003	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH		
	NM	WO 03/070691 A1	8/28/2003	OSAKA INDUSTRIAL PROMOTION ORGANIZATION		
	NN	WO 03/070754 A1	8/28/2003	HORINOUCI, Sueharu		
	NO	WO 2003/075839 A2 & A3	9/18/2003	ATON PHARMA, INC.		
	NP	WO 03/075929 A1	9/18/2003	JANSSSEN PHARMACEUTICA N.V.		
	NQ	WO 03/076395 A1	9/18/2003	JANSSSEN PHARMACEUTICA N.V.		
	NR	WO 03/076400 A1	9/18/2003	JANSSSEN PHARMACEUTICA N.V.		
	NS	WO 03/076401 A1	9/18/2003	JANSSSEN PHARMACEUTICA N.V.		
	NT	WO 03/076421 A1	9/18/2003	JANSSSEN PHARMACEUTICA N.V.		
	NU	WO 03/076422 A1	9/18/2003	JANSSSEN PHARMACEUTICA N.V.		
	NV	WO 03/076430 A1	9/18/2003	JANSSSEN PHARMACEUTICA N.V.		
	NW	WO 03/076438 A1	9/18/2003	JANSSSEN PHARMACEUTICA N.V.		
	NX	WO 03/080864 A1	10/2/2003	EXHONIT THERAPEUTICS SA		
	NY	WO 03/082288 A1	10/9/2003	PROLIFIX LIMITED		
	NZ	WO 03/083067 A2	10/9/2003	BRIGHAM AND WOMEN'S HOSPITAL, INC.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/803,580
				Filing Date	March 17, 2004
				First Named Inventor	Jerome C. Bressi
				Group Art Unit	1625
				Examiner Name	Celia C. Chang
Sheet	12	of	15	Attorney Docket Number	HDAC-5005-C2

	OA	WO 03/084611 A1	10/16/2003	GOVERNMENT OF UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES		
	OB	WO 03/086397 A1	10/23/2003	KOWA CO., LTD.		
	OC	WO 03/087057 A1	10/23/2003	ASTRAZENECA AB		
	OD	WO 03/087066 A1	10/23/2003	IN2GEN CO., LTD.		
	OE	WO 03/088954 A1	10/30/2003	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH		
	OF	WO 03/092686 A1	11/13/2003	ASTRAZENECA AB		
	OG	WO 03/099210 A3	12/4/2003	REGENTS OF UNIVERSITY OF CALIFORNIA		
	OH	WO 03/099272 A1	12/4/2003	BEACON LABORATORIES, INC.		
	OI	WO 03/099760 A1	12/4/2003	BEACON LABORATORIES, INC.		
	OJ	WO 03/099789 A1	12/4/2003	BEACON LABORATORIES, INC.		
	OK	WO 03/100089 A1	12/4/2003	REGENTS OF UNIVERSITY OF CALIFORNIA		
	OL	WO 2003/103613 A2 & A3	12/18/2003	REGENTS OF UNIVERSITY OF CALIFORNIA		
	OM	WO 03/103712 A1	12/18/2003	NOVARTIS AG		
	ON	WO 2004/001072 A2	12/31/2003	JAPAN AS REPRESENTED BY THE PRESIDENT OF THE UNIVERSITY OF TOKYO		
	OO	WO 04/002944 A1	1/8/2004	PHARMACIA & UPJOHN COMPANY		
	OP	WO 2004/005282 A1	1/15/2004	NOVARTIS AG		
	OQ	WO 2004/005513 A2	1/15/2004	METHYLGENE, INC.		
	OR	WO 2004/006909 A1	1/22/2004	TITAN PHARMACEUTICALS, INC.		
	OS	WO 2004/009092 A1	1/29/2004	CHEMGENEX THERAPEUTICS, INC.		
	OT	WO 2004/009536 A1	1/29/2004	G2M CANCER DRUGS AG		
	OU	WO 2004/009771 A2	1/29/2004	ADVANCED STENT TECHNOLOGIES, INC.		
	OV	WO 2004/013130 A1	2/12/2004	ARGENTA DISCOVERY LIMITED		
	OW	WO 04/017996 A1	3/4/2004	YAMANOUCHI PHARMACEUTICAL CO., LTD.		
	OX	WO 2004/020460 A1	3/11/2004	YAMANOUCHI PHARMACEUTICAL CO., LTD.		
	OY	WO 2004/024160 A1	3/25/2004	MCGUIRE VA MEDICAL CENTER 111K		
	OZ	WO 2004/026234 A2	4/1/2004	UNIVERSITY OF SOUTH FLORIDA		
	PA	WO 2004/027418 A3	4/1/2004	FORSCHUNGSZENTRUM KARLSRUHE GMBH		
	PB	WO 2004/029622 A2	4/8/2004	G2M CANCER DRUGS AG		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/803,580
				Filing Date	March 17, 2004
				First Named Inventor	Jerome C. Bressi
				Group Art Unit	1625
Examiner Name	Celia C. Chang				
Sheet	13	of	15	Attorney Docket Number	HDAC-5005-C2

	PC	WO 2004/031388 A1	4/15/2004	SONY CORPORATION		
	PD	WO 2004/035525 A1	4/29/2004	METHYLGENE INC.		
	PE	WO 2004/043352 A2	5/27/2004			
	PF	WO 2004/043348 A2	5/27/2004	ALCON, INC.		
	PG	WO 2004/046094 A1	6/3/2004	BARTS AND THE LONDON NHS TRUST		
	PH	WO 2004/046104 A2	6/3/2004	CIRCAGEN PHARMACEUTICAL		
	PI	WO 2004/046312 A2	6/3/2004	BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS		
	PJ	WO 04/052292 A2	6/24/2004	UNIVERSITY OF SOUTH FLORIDA,		
	PK	WO 04/052838 A1	6/24/2004	F. HOFFMANN-LA ROCHE AG		
	PL	WO 04/053140 A2	6/24/2004	JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH		
	PM	WO 04/054999 A1	7/1/2004	F. HOFFMANN-LA ROCHE AG		
	PN	WO 04/056877 A1	7/8/2004	SINTOFARM S.P.A.,		
	PO	WO 04/063146 A1	7/29/2004	ITALFARMACO SPA		
	PP	WO 04/063169 A1	7/29/2004	FUJISAWA PHARMACEUTICAL CO.		
	PQ	WO 04/064727 A2	8/5/2004	GEORGETOWN UNIVERSITY		
	PR	WO 04/065354 A1	8/5/2004	TOPOTARGET UK LIMITED		
	PS	WO 04/067480 A2	8/12/2004	OXFORD GLYCOSCIENCES (UK) LTD		
	PT	WO 2004/069133 A2	8/19/2004	F. HOFFMANN-LA ROCHE AG		
	PU	WO 2004/069803 A2	8/19/2004	F. HOFFMANN-LA ROCHE AG		
	PV	WO 2004/069823 A1	8/19/2004	METHYLGENE, INC.		
	PW	WO 2004/070351 A2	8/19/2004	ODYSSEY THERA, INC.		
	PX	WO 2004/071400 A2	8/26/2004	SHENZHEN CHIPSCREEN BIOSCIENCES LTD.		
	PY	WO 2004/071401 A2	8/26/2004	FUJISAWA PHARMACEUTICAL CO., LTD.		
	PZ	WO 2004/071443 A2	8/26/2004	IRM LLC		
	QA	WO 2004/071464 A2	8/26/2004	JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE		
	QB	WO 2004/072047 A1	8/26/2004	FUJISAWA PHARMACEUTICAL CO., LTD.		
	QC	WO 2004/072265 A2	8/26/2004	WYETH		
	QD	WO 2004/074478 A1	9/2/2004	FUJISAWA PHARMACEUTICAL CO., LTD.		
	QE	WO 04/076386 A2	9/10/2004	TOPOTARGET UK LIMITED		
	QF	WO 04/082638 A2	9/30/2004	SYRRX, INC.,		
	QG	WO 2004/089293 A2	10/21/2004	TRUSTEES OF COLUMBIA UNIVERSITY IN CITY OF NEW YORK		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/803,580		
		Filing Date	March 17, 2004		
		First Named Inventor	Jerome C. Bressi		
		Group Art Unit	1625		
		Examiner Name	Celia C. Chang		
Sheet	14	of	15	Attorney Docket Number	HDAC-5005-C2

	QH	WO 2004/092115 A2	10/28/2004	AXYS PHARMACEUTICALS INC.		
	QI	WO 2004/098495 A2	11/18/2004	TRUSTEES OF COLUMBIA UNIVERSITY IN CITY OF NEW YORK		
	QJ	WO 04/103358 A2	12/2/2004	NOVARTIS AG		
	QK	WO 04/103369 A1	12/2/2004	SCHERING AKTIENGESELLSCHAFT		
	QL	WO 04/110418 A2	12/23/2004	KALYPSYS, INC.		
	QM	WO 04/112763 A2	12/29/2004	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS		
	QN	WO 04/113336 A1	12/29/2004	CHROMA THERAPEUTICS LIMITED		
	QO	WO 2005/000213 A2	1/6/2005	KOSAN BIOSCIENCES, INC.		
	QP	WO 2005/000282 A2	1/6/2005	G2M CANCER DRUGS AG		
	QQ	WO 2005/000289 A1	1/6/2005	G2M CANCER DRUGS AG		
	QR	WO 2005/000332 A2	1/6/2005	FUJISAWA PHARMACEUTICAL CO., LTD.		
	QS	WO 05/002555 A2	1/13/2005	PRESIDENT AND FELLOWS OF HARVARD COLLEGE,		
	QT	WO 05/002672 A2	1/13/2005	PRESIDENT AND FELLOWS OF HARVARD COLLEGE		
	QU	WO 05/004861 A1	1/20/2005	KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY		
	QV	WO 2005/007091 A2	1/27/2005	GEORGETOWN UNIVERSITY		
	QW	WO 2005/007158 A1	1/27/2005	OHIO STATE UNIVERSITY RESEARCH FOUNDATION		
	QX	WO 2005/009349 A2	2/3/2005	SUPERGEN, INC.		
	QY	WO 05/011598 A2	2/10/2005	UNIVERSITY OF SOUTH FLORIDA		
	QZ	WO 05/011661 A1	2/10/2005	UNIVERSITY COLLEGE LONDON		
	RA	WO 05/013958 A1	2/17/2005	NOVARTIS AG		
	RB	WO 05/014004 A1	2/17/2005	NOVARTIS AG		
	RC	WO 05/014588 A1	2/17/2005	ARGENTA DISCOVERY LIMITED		
	RD	WO 05/016264 A2	2/24/2005	AVALON PHARMACEUTICALS,		
	RE	WO 2005/016342 A1	2/24/2005	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY		
	RF	WO 05/018578 A2	3/3/2005	ATON PHARMA, INC.		
	RG	WO 05/019174 A1	3/3/2005	AXYS PHARMACEUTICALS, INC.,		
	RH	WO 05/023179 A2	3/17/2005	ATON PHARMA, INC.		
	RI	WO 05/025619 A1	3/24/2005	NOVARTIS AG		
	RJ	WO 05/028447 A1	3/31/2005	S'BIO PTE LTD		
	RK	WO 05/028620 A2	3/31/2005	ROCKEFELLER UNIVERSITY		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/803,580
				Filing Date	March 17, 2004
				First Named Inventor	Jerome C. Bressi
				Group Art Unit	1625
Examiner Name	Celia C. Chang				
Sheet	15	of	15	Attorney Docket Number	HDAC-5005-C2

	RL	WO 05/030704 A1	4/7/2005	METHYLGENE, INC.		
	RM	WO 05/030705 A1	4/7/2005	METHYLGENE, INC.		
	RN	WO 05/034880 A2	4/21/2005	ATON PHARMA, INC.		
	RO	WO 2005/039498 A2	5/6/2005	ATON PHARMA, INC.		
	RP	WO 2005/040101 A1	5/6/2005	S'BIO PTE LTD		
	RQ	WO 2005/040136 A1	5/6/2005	BRISTOL-MYERS SQUIBB COMPANY		
	RR	WO 2005/040161 A1	5/6/2005	S'BIO PTE LTD		
	RS	WO 05/047457 A2	5/26/2005	JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH		
	RT	WO 05/051901 A1	6/9/2005	UNIVERSITY OF QUEENSLAND		
	RU	WO 2005/053609 A2	6/16/2005	GUILFORD PHARMACEUTICALS INC.		
	RV	WO 2005/053610 A2	6/16/2005	ATON PHARMA, INC.		
	RW	WO 05/055928 A2 & A3	6/23/2005	OHIO STATE UNIVERSITY RESEARCH FOUNDATION		
	RX	WO 05/058298 A2	6/30/2005	WISCONSIN ALUMNI RESEARCH FOUNDATION		
	RY	WO 05/058803 A1	6/30/2005	EXONHIT THERAPEUTICS SA		
	RZ	WO 2005/065681 A1	7/21/2005	SYRRX, INC.		
	SA	WO 2005/066151 A2	7/21/2005	SYRRX, INC.		
	SB	WO 05/071079 A1	8/4/2005	ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.